<DOC>
	<DOC>NCT00637806</DOC>
	<brief_summary>To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.</brief_summary>
	<brief_title>Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Cancer of multiple types in stage II, III, or IV and not a candidate for chemotherapy; but may have been receiving radiation therapy Fair, poor, or very poor appetite Cancerassociated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months) Weight loss perceived to be associated with diminished appetite Eastern Cooperative Oncology Group Performance score of 0, 1, or 2 Life expectancy greater than 3 months Alert and mentally competent to complete study assessments Women of childbearing potential required to use an adequate and reliable method of contraception. Postmenopausal women have to have been so for at least 1 year Screening laboratory values must not be clinically significant (some exceptions per protocol) Brain, or head and neck tumors that may interfere with food consumption AIDSrelated wasting Radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption Presence of conditions that interfere with oral intake or ability to swallow Absence of normally functioning gut Known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome Intractable or frequent vomiting Clinically significant diarrhea History of thromboembolic events, or on longterm anticoagulation for thromboembolism Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism Poorly controlled hypertension or congestive heart failure Pregnant/lactating females, or planning on becoming pregnant Use of appetite stimulants within past 30 days Use of parenteral nutrition or tube feedings within past 1 week Chronic use of steroids within past 3 months (intermittent shortterm use allowed) Current use of illicit substances Allergy, hypersensitivity, or other contraindication to megestrol acetate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Megestrol acetate</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Unintended weight loss</keyword>
	<keyword>Body weight</keyword>
	<keyword>Appetite</keyword>
	<keyword>Megace ES</keyword>
</DOC>